<div id="readability-page-1"><p>Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) has been given an average rating of &#34;Buy&#34; by the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $35.00.</p><div><p><span></span><span>Get <strong>Alto Neuroscience</strong> alerts:</span></p></div><p>A number of analysts recently commented on ANRO shares. William Blair reiterated an &#34;outperform&#34; rating on shares of Alto Neuroscience in a report on Wednesday, June 12th. Rodman &amp; Renshaw initiated coverage on Alto Neuroscience in a report on Friday, June 21st. They set a &#34;buy&#34; rating and a $43.00 target price for the company.</p><p><b>View Our Latest Analysis on Alto Neuroscience</b></p><h2>Alto Neuroscience Stock Down 8.0 %</h2><p>Shares of NYSE ANRO opened at $8.37 on Friday. Alto Neuroscience has a one year low of $8.15 and a one year high of $24.00. The company has a current ratio of 26.02, a quick ratio of 26.02 and a debt-to-equity ratio of 0.05. The firm has a fifty day moving average price of $12.07. </p><p>Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.30). Equities research analysts expect that Alto Neuroscience will post -2.93 EPS for the current year. </p><h2>Insider Activity</h2><p>In other Alto Neuroscience news, insider Adam Savitz bought 12,069 shares of the business's stock in a transaction dated Tuesday, July 9th. The shares were purchased at an average price of $12.60 per share, with a total value of $152,069.40. Following the completion of the purchase, the insider now owns 36,920 shares in the company, valued at approximately $465,192. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. </p><h2>Institutional Trading of Alto Neuroscience</h2><p>Hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers acquired a new stake in Alto Neuroscience during the 2nd quarter worth about $113,000. Federated Hermes Inc. grew its position in Alto Neuroscience by 33.3% during the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company's stock worth $128,000 after purchasing an additional 3,000 shares during the period. Bank of New York Mellon Corp acquired a new stake in Alto Neuroscience during the 2nd quarter worth about $252,000. University of Texas Texas AM Investment Managment Co. acquired a new stake in shares of Alto Neuroscience during the 1st quarter valued at about $340,000. Finally, Bowie Capital Management LLC acquired a new stake in shares of Alto Neuroscience during the 2nd quarter valued at about $462,000. </p><h2>About Alto Neuroscience</h2> (Get Free Report<p>Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Alto Neuroscience</li><li>3 Fintech Stocks With Good 2021 Prospects</li><li>The Cannabis Sector: Profitability Takes Center Stage</li><li>Health Care Stocks Explained: Why You Might Want to Invest</li><li>Amazon’s Stock Plunge: Is a Prime Buying Opportunity Knocking?</li><li>Consumer Discretionary Stocks Explained</li><li>Buy the Dip in e.l.f. Beauty: Analysts Point to a New High</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFOUk8?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFOUk8"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ Kamala Harris’ Woke Politics Could Lead to 50% Stock Collapse <span><span>(From Paradigm Press)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTIz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTIz"/></p><h2>Should you invest $1,000 in Alto Neuroscience right now?</h2><p>Before you consider Alto Neuroscience, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alto Neuroscience wasn't on the list.</p><p>While Alto Neuroscience currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p> </div>

ANRO

<p>Alto Neuroscience, Inc. (NYSE:ANRO) has received an average "Buy" rating from six analysts. The stock has a 12-month target price of $35.00. Insider activity includes an insider buying 12,069 shares of the stock. The company operates as a clinical-stage biopharmaceutical company.</p>

Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of "Buy" from Analysts